Inquiry Basket
Loading ......
Polyomaviruses are a family of small, non-enveloped DNA viruses that establish persistent, lifelong infections in a wide range of vertebrate hosts, including humans. The name "polyomavirus" derives from the Greek words poly (many) and oma (tumours), reflecting their capacity to induce multiple tumours when experimentally inoculated into neonatal rodents. While these viruses typically remain asymptomatic in immunocompetent individuals, they pose significant health risks in immunocompromised populations, where reactivation can lead to severe and sometimes fatal diseases. The family Polyomaviridae has expanded dramatically since the discovery of BK polyomavirus (BKPyV) and JC polyomavirus (JCPyV) in 1971, with over a dozen novel human polyomaviruses identified in the past two decades. Among these, Merkel cell polyomavirus (MCPyV) has been unequivocally linked to Merkel cell carcinoma, a rare but aggressive skin cancer, cementing the oncological significance of this virus family. This article synthesises current knowledge on polyomavirus virology, replication dynamics, key molecular targets, and clinical implications.
Figure 1. The structure of an infectious human polyomavirus. (Hurdiss D L, et al. 2018)
Polyomaviruses belong to the family Polyomaviridae, which comprises three genera: Orthopolyomavirus and Wukipolyomavirus (infecting mammals) and Avipolyomavirus (infecting birds). The most clinically relevant human pathogens—BKPyV, JCPyV, and MCPyV—are classified within the Orthopolyomavirus genus. These viruses possess a circular, double-stranded DNA genome of approximately 5,000 base pairs, packaged with cellular histones into a minichromosome structure within the icosahedral capsid. The genome is organised into three functional regions: the early region, the late region, and the non-coding control region (NCCR). The NCCR contains the origin of replication and multiple transcription factor binding sites that regulate viral gene expression. The early region encodes regulatory proteins—large T antigen (LT) and small T antigen (sT)—produced through alternative splicing of a common transcript. These multifunctional oncoproteins drive viral replication and subvert host cell cycle controls. The late region encodes the structural capsid proteins VP1, VP2, and VP3, which assemble into the viral capsid. Additionally, BKPyV, JCPyV, and simian virus 40 (SV40) encode agnoprotein, a small regulatory phosphoprotein that enhances viral propagation and modulates host cell functions.
Polyomaviruses encode a limited repertoire of viral proteins that interface with an extensive network of host cellular factors to establish infection, subvert antiviral defences, and drive oncogenic transformation. Understanding these molecular interactions at the level of specific genes provides critical insights for therapeutic development.
| Key Molecular Targets | Details |
| Cytokine and Chemokine Dysregulation | Polyomavirus infection modulates expression of numerous inflammatory mediators. Reactivation is associated with increased levels of tumour necrosis factor (TNF), interleukin-6, and other pro-inflammatory cytokines that contribute to tissue pathology. Agnoprotein-mediated chemokine regulation may alter local immune responses, promoting viral persistence. |
| Host Factors Exploited for ER Transport | Polyomaviruses hijack components of the ERAD machinery to penetrate the ER membrane, a decisive step in infection. This process involves host factors including Derlin-1 (DERL1), SEL1L, and the ATPase p97 (VCP), which are co-opted to facilitate viral escape into the cytosol. |
| JAK/STAT Signalling Interference | While direct targeting of JAK/STAT components is less well characterised in polyomaviruses compared to other viral families, emerging evidence suggests that these viruses modulate STAT signalling. The interplay between viral proteins and host transcription factors ultimately affects STAT-dependent gene expression, contributing to immune evasion. |
Human polyomaviruses (HPyVs) are highly host-specific, and most establish asymptomatic latent infections in healthy individuals, with seroprevalence increasing with age. Since 2007, seven additional human polyomaviruses have been identified, expanding the family. These include Merkel cell polyomavirus (MCV), discovered in Merkel cell carcinoma (a rare skin cancer); Trichodysplasia spinulosa-associated polyomavirus (TSV), isolated from a rare skin hyperplasia in transplant patients; and Wu polyomavirus (WUV), Ki polyomavirus (KIV), human polyomavirus 6 (HPyV6), HPyV7, and HPyV9, which have not yet been clearly linked to human disease. Simian virus 40 (SV40), a primate polyomavirus, is also notable as a contaminant in polio vaccines administered between 1955 and 1963, exposing millions of individuals to the virus.
Polyomaviruses primarily cause disease in immunocompromised individuals, where latent infections reactivate, leading to lytic replication and tissue damage. In immunocompetent hosts, primary infection (typically acquired in childhood via fecal-oral, respiratory, or urinary routes) is usually asymptomatic, and the virus establishes latency in tissues such as the kidneys, bladder, bone marrow, and lymphoid organs. Latency is maintained by the host immune system, and reactivation occurs when immune function is impaired—for example, in transplant recipients on immunosuppressive therapy, HIV/AIDS patients, or individuals receiving chemotherapy. The most well-characterized clinical manifestations of human polyomavirus infections include: BKPyV-associated hemorrhagic cystitis (common in allogeneic hematopoietic stem cell transplant recipients) and polyomavirus nephropathy (in renal transplant patients).
Management of polyomavirus-associated diseases remains challenging, with no approved antiviral therapies currently available. Reduction of immunosuppression is the cornerstone of management for BKPyV nephropathy, allowing host immune responses to control viral replication. Emerging therapies include virus-specific T-cell therapies, monoclonal antibodies targeting BKPyV, and antiviral antisense oligonucleotides that inhibit T antigen expression. Intravenous immunoglobulin (IVIg) containing neutralising antibodies may serve as adjunctive therapy. Understanding the molecular targets detailed above—including LT helicase, viral receptors, and host factors exploited during replication—continues to inform rational drug design.
Polyomaviruses are a diverse and ubiquitous family of viruses with significant implications for human health, particularly in immunocompromised individuals. Their ability to establish lifelong latent infections and reactivate to cause severe disease highlights the importance of understanding their biology, pathogenesis, and molecular targets. This resource article provides a comprehensive overview of polyomaviruses, covering their structure, classification, clinical manifestations, key molecular targets, and current research directions. As research advances, further insights into viral-host interactions and the development of targeted therapies will be critical for improving the management and prevention of polyomavirus-associated diseases.
Reference
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| BKV MT | DMAB7134 | Anti-Polyomavirus PyMT Monoclonal antibody, Clone Hmv-Hmv | Mouse | IgG1 | IF, WB, IP | Inquiry |
| DMABT-Z60955 | Anti-Polyomavirus Medium T Monoclonal antibody, Clone RaOV | Rat | IgG2b | IP, ICC, IF, WB | Inquiry | |
| BKV LT | DMABT-Z59919 | Anti-Polyomavirus Large T antigen Monoclonal antibody, Clone RaLV | Rat | IgG2b | WB, IP, ICC, IF | Inquiry |
| BKV Early Antigen | DMABT-Z60972 | Anti-Polyomavirus Early Antigen Monoclonal antibody, Clone RaE | Rat | IgG2b | WB, IP, ICC, IF | Inquiry |
| Target | Cat. No. | Product Name | Host | |
| BKV VP1 | DAG-P2869 | Polyomavirus Major Capsid VP1 (full length) | S. cerevisiae | Inquiry |
| BKV VP1 | DAG-P2869 | Polyomavirus Major Capsid VP1 (full length) | S. cerevisiae | Inquiry |
| JCV VP1 | DAG-WT3382 | Native Polyomavirus Antigen | N/A | Inquiry |
Loading ......
